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Emily V. Nosova, BA,a,b Michael S. Conte, MD,a,c and S. Marlene Grenon, MD,a,b,d San Francisco, Calif
Objective: Peripheral arterial disease (PAD) is a burdensome cardiovascular condition that results from chronic inﬂam-
matory insults to the arterial vasculature. Key risk factors include age, gender, type 2 diabetes mellitus, hypertension,
hypercholesterolemia, hyperhomocysteinemia, smoking, lack of physical ﬁtness, and poor diet, the latter three being
modiﬁable in the development and progression of PAD. A growing body of evidence indicates that imbalanced nutrient
intake may contribute to the development and progression of PAD. The purpose of this review is to summarize current
knowledge about nutritional patterns among patients with PAD and to ascertain whether certain health-promoting foods
and nutrients could beneﬁt patients with this condition.
Methods:We conducted a comprehensive literature review to examine primary source evidence for or against the nutrients
that are commonly associated with PAD and their potential utility as therapies.
Results: We summarized nine categories of nutrients, as well as four diets endorsed by the American Heart Association
that may be prescribed to patients with or at risk for PAD. The nutrients reviewed included omega-3 polyunsaturated
fatty acids (n-3 PUFAs), folate and B-series vitamins, and antioxidants. The diet plans described include the Dietary
Approaches to Stop Hypertension (DASH) diet, Mediterranean diet, low-fat diet, low carbohydrate diet, Dr Dean
Ornish’s Spectrum Diet and Dr Andrew Weil’s Anti-Inﬂammatory Diet.
Conclusions: PAD is a chronic inﬂammatory condition that is associated with longstanding poor nutrition habits. We
advocate for an intensiﬁed use of diet in PAD therapy, and we speciﬁcally recommend following eating patterns that are
rich in nutrients with anti-inﬂammatory and antioxidant properties. (J Vasc Surg 2015;61:265-74.)Peripheral arterial disease (PAD) is a burdensome car-
diovascular condition that results from chronic inﬂamma-
tory insults to the arterial vasculature.1,2 Key risk factors
include age, gender, type 2 diabetes mellitus, hypertension,
hypercholesterolemia, hyperhomocysteinemia, smoking,
lack of physical ﬁtness, and poor diet,2,3 the latter three be-
ing modiﬁable in the development and progression of
PAD.
An insidious asymptomatic period typically makes
PAD an underdiagnosed condition. PAD is a common
disorder affecting up to 12 million Americans and 20%
of patients in primary care; nearly one-third of patients
aged $70 will suffer from PAD,3 which signiﬁcantly af-
fects their quality of life and longevity. In light of recent
reports that PAD is a global disease affecting >200
million individuals, with an incidence that has increased
by nearly a quarter in the last decade,4 stronger efforts
need to be focused on primary and secondary risk reduc-
tion. Among the most concerning sequelae of advanced
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://dx.doi.org/10.1016/j.jvs.2014.10.022pain, nonhealing wounds, and limb loss.5-9 Despite the
available medical therapies, patients with PAD continue
to have a higher risk for cardiovascular events compared
with patients with coronary artery disease (CAD)10-12
and a threefold to ﬁvefold increased risk of cardiovascular
mortality compared with age-matched controls.13 Hospi-
talizations and treatment associated with PAD impart a
signiﬁcant ﬁnancial burden on the health care system.
Each year >$21 billion is spent on PAD treatment in
the United States.14 Mainstays of treatment include med-
ical therapies, exercise, vascular bypass operations, and
endovascular procedures. Although these interventions
are often helpful, it is not uncommon that patients expe-
rience postoperative complications, have recurrent symp-
toms, or require repeat treatments, which further
increase the costs associated with PAD.15
A growing body of evidence indicates that imbalanced
nutrient intake may contribute to the development and
progression of PAD.16-24 Promoting better nutrition may
reduce oxidative stress, enhance endothelial cell function,
and improve erythrocyte deformability, blood viscosity,
and oxygen perfusion in atherosclerosis-induced muscle
ischemia, all of which could lead to improvements in clin-
ical outcomes.25 A primary prevention approach incorpo-
rating nutritional therapy may be advantageous in
decreasing rates of PAD, whereas a secondary prevention
approach may be useful in treating symptoms of PAD or
slowing its progression. The purpose of this review is to
summarize current knowledge about nutritional patterns
among patients with PAD and to ascertain whether certain
health-promoting foods and nutrients could beneﬁt pa-
tients with this condition. This review is meant to provide
a comprehensive overview of primary source evidence265
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to this ﬁeld.
CURRENT DIETARY GUIDELINES AND
RECOMMENDATIONS
The 2013 composite American Heart Association
(AHA) and American College of Cardiology (ACC) Task
Force Guidelines26 address nutrition-focused risk reduction
strategies for cardiovascular disease in a broad context, with
the aim of improving public health. The guidelines endorse
a “Heart Healthy Lifestyle”26 and provide a general frame-
work for incorporating healthy nutrition into lifestyle man-
agement to improve blood pressure and lipid control. They
emphasize broad nutrient categories that are associated
with better cardiovascular outcomes (eg, fruits and vegeta-
bles, whole grains, legumes, etc), although an important
limitation is that particular nutrients that may beneﬁt
patients with advanced cardiovascular disease are not
explicitly identiﬁed. The most speciﬁc suggestions are
embedded in recommendations for lowering low-density
lipoprotein cholesterol: the task force advises obtaining a
maximum of 5% to 6% of total calories from saturated
fat, reducing dietary monounsaturated fats (eg, oleic acid
found in olive oil), and minimizing intake of foods rich
in trans-fats (found in milk, animal fats, and some vege-
table oils).
The AHA/ACC Task Force Guidelines are signiﬁcant
for incorporating the latest high-quality clinical trial evi-
dence and promoting preventive strategies for the general
population as a means of improving cardiovascular health.
However, we remain without speciﬁc direction in regards
to PAD, a disease at the severe end of the atherosclerotic
syndromes. Compared with healthy individuals and those
with mild coronary disease, individuals with PAD tend to
have a greater systemic inﬂammatory burden, higher blood
pressure, higher triglyceride levels, and deﬁciencies in
various antioxidants and minerals.16,27 Furthermore, our
own experience demonstrates that the mortality rate
among patients with PAD is double that of patients with
CAD only.28 We, therefore, advocate that beneﬁcial nutri-
ents have a stronger role in cardiovascular risk prevention
for people at risk for or with diagnosed PAD.
Studies published on nutrition as a means of prevention
often have conﬂicting results, and when disseminated in
mass media, they may spark confusion about which nutri-
ents are actually beneﬁcial or which diet is most healthy.
The most recent example pertains to reports that saturated
fats29,30 may have relatively neutral effects on cardiovascu-
lar disease, a notion that directly conﬂicts with the current
AHA/ACC guidelines. A more valuable approach in
advising patients with PAD would be to promote a diet
that is specialized to address the nutritional alterations asso-
ciated with this condition and that promotes intake of anti-
inﬂammatory and antioxidant rich foods. In fact, recent
reports have demonstrated that therapies speciﬁcally
focused on nutrition and weight reduction in PAD may
lead to improvements in functional impairment and
ischemic outcomes.16Nutritional intake and average dietary patterns among
patients with PAD have previously been evaluated. Gardner
et al31 demonstrated that PAD and the presence of claudi-
cation are associated with a diet high in saturated fat, so-
dium, and cholesterol and low in ﬁber, vitamin E, and
folate intake. In another study by Antonelli-Incalzi
et al,32 similar patterns were evident: PAD patients had
lower consumption of vegetables, ﬁber, vitamins C and
E, folate, and long-chain polyunsaturated fatty acids
(PUFAs) compared with individuals without PAD.
Notably, these cross-sectional studies had relatively small
sample sizes and their data were derived from self-
reported answers to dietary questionnaires. Despite these
limitations, these studies are still instructive and help to
inform our understanding of an average nutritional proﬁle
in patients with PAD.
Larger analyses using population-based data have also
been conducted. In their study of the United States Na-
tional Health and Nutrition Examination Survey
(NHANES) data, which included 7200 patients, Lane
et al.21 found that consumption of vitamins A, C, E, B6,
and B12 were associated with a lower odds of having
PAD. Further analysis indicated that intake of ﬁber, vita-
mins A, C, E, B6, folate, and n-3 PUFAs correlated with
a reduced prevalence of PAD. Most recently, Naqvi
et al33 analyzed the associations between PAD (ankle-
brachial index <0.9) and nutrient intake among partici-
pants from the NHANES. They found inverse associations
between the incidence of PAD and intake of folate and vi-
tamins A, B6, C, and E, afﬁrming the results observed by
Lane et al21 and the smaller cross-sectional studies
described previously. However, after adjusting for energy
intake and physical activity, odds ratios between the PAD
and non-PAD groups were no longer statistically
signiﬁcant.
Knowledge about speciﬁc nutritional deﬁciencies can
help guide therapeutic efforts. Achieving a better under-
standing of diet in PAD may also facilitate the design and
execution of prospective and randomized trials with clinical
outcomes such as major adverse cardiovascular events and
limb-related end points such as claudication distance,
limb revascularization, and amputation. Furthermore, if
physicians and health professionals have a better under-
standing of speciﬁc nutrients and their effects on athero-
sclerotic progression, they can be better equipped to give
advice about healthful nutrition. The chief nutrients that
have been associated with atherosclerosis include n-3
PUFAs, folate and B-series vitamins, and antioxidants
(Table I), each of which is reviewed below. Additional nu-
trients, in particular sodium, saturated fats, and ﬁber, have
also been strongly linked to atherosclerosis riskdthese have
been extensively evaluated in prior studies in relation to
cardiovascular outcomes, are associated with strong (grade
I) recommendations from the AHA/ACC and will not be
discussed here.34 To identify primary sources, we searched
PubMed/MEDLINE and the Cochrane database and we
considered studies for inclusion if they were published in
1990 or more recently.
Table I. Nutrient recommendations based on the 2013 American Heart Association/American College of Cardiology
(AHA/ACC) National Guidelines for Cardiovascular Disease
Nutrient Recommendation
Organization
afﬁliated with
recommendation
Strength of
evidencea
Level of
evidenceb
n-3 PUFAs d Daily 1.6 grams EPA þ DHA
For primary prevention:
d Consume fatty ﬁsh (eg, salmon, tuna, mackerel) 2 week. Each
ﬁsh portion should be 55-85 g and supply $500-1000 mg
EPA þ DHA
d Alternative: daily n-3 PUFAs supplements containing 1 g
EPA þ DHA
Secondary prevention:
d For individuals who do not typically eat ﬁsh, daily n-3 PUFAs
supplements containing 1 g EPA þ DHA may be beneﬁcial
IOMc
AHA/ACCd
IIa
IIb
IIb
A
B
A
Folate, vitamins
B6 and B12
d Daily intake of 400 g/1.7 mg/2.4 mg
d Folic acid, vitamin B supplements not recommended for
primary or secondary prevention of cardiovascular disease
IOM
AHA/ACC III A
Vitamin C d No recommendations for antioxidant vitamin supplements to
prevent or treat cardiovascular disease
AHA/ACC III C
Vitamin D d Daily intake of 700 IU
d No supplementation recommendation for cardiovascular
disease prevention in individuals with normal vitamin D levels.
d Correction of low vitamin D levels may reduce cardiovascular
disease morbidity and mortality
IOM
AHA/ACC III
IIb
C
B
Vitamin E d No recommendations for antioxidant vitamin supplements to
prevent or treat cardiovascular disease
AHA/ACC III C
Coenzyme Q10 d No speciﬁc recommendations regarding primary or secondary
risk reduction
d Long-term effects of supplementation in patients with conges-
tive heart failure and/or taking statins not yet established
Therefore, supplementation with coenzyme Q10 not recom-
mended in these patients
d Short-term coenzyme Q10 supplementation may lead to mild
blood pressure improvement and increases in ejection fraction
in patients with CHF
AHA/ACC III
IIb
B
B
Saturated fat d Reduce saturated fat intake to 5-6% of total daily caloric intake AHA/ACC I A
Sodium d Daily maximum: 1250 mg
d Daily sodium intake should be restricted to 2.3 g (w6 g/d salt)
IOM
AHA/ACC I B
Dietary ﬁber d Daily 30 g intake
d Recommended dietary ﬁber intake is 14 g/1000 kcal, or 25 g
for adult women and 38 g for adult men
d Recommended to increase dietary ﬁber intake in order to
reduce blood LDL-C and glucose
IOM
AHA/ACC IIa
I
B
A
CHF, Congestive heart failure; DHA, docosahexanoic acid; EPA, eicosapentaenoic acid; LDL-C, low-density lipoprotein; n-3 PUFA, omega-3 poly-
unsaturated fatty acid.
aStrength of statement/recommendation: Class IdEvidence and/or general agreement that a given statement and/or recommendation is beneﬁcial; Class
IIdConﬂicting evidence and/or a divergence of opinion about the usefulness/efﬁcacy of the statement and/or recommendation; Class IIadWeight of
evidence/opinion is in favor of usefulness/efﬁcacy; Class IIbdUsefulness/efﬁcacy is less well established by evidence/opinion; Class IIIdEvidence or general
agreement that the treatment is not useful/effective and, in some cases, may be harmful.
bLevels of evidence: AdData derived from multiple randomized clinical trials or meta-analyses; BdData derived from a single randomized clinical trial or large
non-randomized studies; CdConsensus of opinion of the experts and/or small studies, retrospective studies, registries.
cIOM: the Institute of Medicine’s Food and Nutrition Board, a branch of the National Academy of Sciences (2010); provides general dietary reference not
based on disease states; retrieved from https://fnic.nal.usda.gov/dietary-guidance/dietary-reference-intakes/dri-tables.
dAHA/ACC: the American Heart Association and American College of Cardiology, composite guidelines for lifestyle management, 2013; source:
Eckel et al.26
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Long-chain n-3 PUFAs, especially from marine sour-
ces, are among the nutrients that have been shown to
reduce systemic inﬂammation35 and protect against endo-
thelial damage and atherosclerosis.36 In a recent meta-anal-
ysis,37 which evaluated the long-term effects of n-3 PUFAs
on secondary prevention of cardiovascular events, authors
found that prolonged supplementation (at least 1 year)
with a minimum 1 g/d eicosapentaenoic (EPA) and doco-
sahexanoic (DHA) acids was protective against death from
cardiac causes, sudden death, and myocardial infarction.
They did not observe a beneﬁt for all-cause mortality or
stroke. However, recent clinical trials have yielded conﬂict-
ing data on the effects of n-3 PUFAs in cardiovascular dis-
eases in general,38-40 results that are likely related to both
the relatively low dose supplemented (averaging 1.5 g/d)
and the heterogeneous cohorts examined.32 Very few
studies have been conducted in the symptomatic PAD
population.41
Table II summarizes the most recent clinical studies
related to the role of n-3 PUFAs in PAD. n-3 PUFAs,
and primarily EPA and DHA, have been shown to
contribute to primary and secondary cardiovascular disease
protection by reducing blood triglyceride concentration,
decreasing production of inﬂammatory cytokines and medi-
ators, lowering blood pressure, increasing nitric oxide (NO)
production and endothelial relaxation and vascular compli-
ance, and decreasing thrombosis and cardiac arrhyth-
mias.2,41 Greater consumption of n-3 PUFAs is associated
with changes in cell membrane composition, which in turn
affects membrane structure and alters membrane protein
function.2 It also leads to a relative decrease in inﬂammatory
signals and monocyte adhesion in the endothelial cells
compared with n-6 PUFAs.42 Furthermore, n-3 PUFAs
compete with n-6 PUFAs, saturated, and trans-fats for inser-
tion into cell membrane and produce less potent inﬂamma-
tory mediators than n-6 PUFAs,25 thereby reducing
inﬂammation within the vessel wall.43
The improvements in endothelial function in particular
are likely due to effects of n-3 PUFAs on ameliorating the
damage caused by exposure to oxidative stress. Increased
dietary intake of ﬁsh or supplementation with n-3 PUFAs
could lead to recovery of endothelial synthesis of NO and
prostaglandin I2, as well as vascular smooth muscle cell
sensitivity to NO. These mechanisms are especially relevant
to patients with PAD, many of who have a long history of
smoking or elevated adiposity, or both, and have proin-
ﬂammatory proﬁles as a result.
In addition to their direct inﬂuences on inﬂammation
and endothelial function, n-3 PUFAs yield potent deriva-
tives, namely protectins, lipoxins, resolvins, and maresins,44
which exert homeostatic effects. These lipid mediators
stimulate and activate endogenous pathways to terminate
and promote the resolution of inﬂammation.2,45 In the
near future, novel anti-inﬂammatory treatments may incor-
porate such resolution-directed therapies,45 which could be
particularly beneﬁcial for patients with PAD.To date, investigations evaluating the role of n-3
PUFAs in PAD have yielded encouraging but mixed re-
sults. Some clinical studies that looked at the effects of sup-
plementation in PAD have demonstrated functional
improvements35 Our group recently conducted clinical
trial randomizing patients with intermittent claudication
to 4.4 g EPA and DHA or placebo (The Effects of
Omega-3 Fatty Acids Supplementation on Endothelial
Function and Inﬂammation [OMEGA-PAD] I Trial
[NCT01310270]) for 1 month. High-dose n-3 PUFA
supplementation altered the lipid metabolome of PAD pa-
tients with a signiﬁcant increase in the production of down-
stream metabolites of n-3 fatty acids including 18-, 15- and
5-hydroxy eicosapentaenoic acids and 4-hydroxy docosa-
hexaenoic acid. Furthermore, there was a signiﬁcant
improvement in triglycerides in the n-3 PUFAs treated
group.46 We are currently enrolling patients for the Effects
of Omega-3 Fatty Acids on Peripheral Arterial Disease
(OMEGA-PAD) II trial, where n-3 PUFAs supplementa-
tion will take place over a longer duration (3 months)
and the main observations will focus on functional out-
comes among claudicant patients with regards to walking
performance (NCT01979874).
Still other trials have found minimal or no beneﬁts. In a
Cochrane review by Sommerﬁeld et al47 evaluating patients
who had intermittent claudication and comparing placebo
with n-3 PUFAs supplementation, there did not appear to
be improvements in quality of life, pain-free walking dis-
tance, maximal walking distance, ankle-brachial index or
angiographic ﬁndings. Reasons for the lack of positive ﬁnd-
ings may be the large range of supplementation duration or
insufﬁcient dosing. Because systemic inﬂammation is
increased in patients with PAD, they may require higher
and more potent dosing, as well as longer (if not lifelong)
therapy to experience biochemical, symptomatic, and mor-
tality beneﬁts. For primary prevention among the general
population, the AHA/ACC guidelines recommend eating
ﬁsh twice weekly, and each ﬁsh portion should range
from 55 to 85 g and supply a minimum of 500 to
1000 mg of EPA plus DHA.34 For individuals with cardio-
vascular disease, the guidelines state that those who do not
regularly eat ﬁsh may consider taking ﬁsh oil supplements
that contain 1 g of EPA plus DHA, based on supplemen-
tation studies in these patients.34 Given the conﬂicting re-
sults regarding n-3 PUFAs in PAD at this point, speciﬁc
dosing recommendations in PAD cannot yet be made.
More randomized trials are warranted that are designed
with adequate dosing schedules, commensurate to the
increased inﬂammatory proﬁle observed in this patient
group.16
In addition to EPA and DHA, another dietary n-3
PUFA that is nutritionally essential is a-linolenic acid.
Some rich sources for a-linolenic acid include ﬂaxseed,
chia seed, walnuts, and soybeans. Flaxseed, in particular,
is increasingly being evaluated as a supplement for cardio-
vascular disease prevention due to its potent antiar-
rhythmic, antiatherogenic and antiinﬂammatory effects.48
Table II. Previous studies evaluating supplementation with omega-3 polyunsaturated fatty acids (n-3 PUFAs) in
peripheral arterial disease (PAD)
First author
(year) Type of study Patients No. Treatment Variables measured Findings
Leng et al
(1998)78
Double-blind,
randomized,
placebo-controlled
M/F, IC 120 1.95 g/d  2 years
(1.68 g-linolenic
acid þ 0.27 g EPA)
Serum cholesterol
lipoprotein
concentrations,
hemostatic and
rheologic variables,
walking distance,
SBP, ABI, nonfatal
coronary events,
death
No change in lipids,
higher hematocrit
in treatment group,
lower SBP
Conway and
Evans (2005)79
Double-blind,
randomized,
placebo-controlled
study
M/F, IC 50 10 g/d ﬁsh oils 
16 weeks (1.7 g
EPA þ1.15 g
DHA)
QOL, ABI, pain-free
walking distance,
walking distance
No change in QOL,
ABI or absolute
walking distance,
increase initial
walking distance
Luu et al
(2007)80
Prospective study IC and controls 16 6 g/d  12 weeks
(1.02 g EPA þ
0.69 g DHA)
Monocytes ability to
induce recruitment
using monocyte
(from PAD
patients) and
endothelial cell
cocultures
No change in
recruitment of
monocytes in PAD.
Less recruitment of
monocytes in
controls after
dietary
supplementation
Madden et al
(2007)35
Prospective study M, IC 16 6 g/d  12 weeks
(1.02 g EPA þ
0.69 g DHA)
Walking distance, ABI Increase in walking
distance to ﬁrst pain
and total walking
distance, increase in
ABI
Schiano et al
(2008)81
Single-blinded,
randomized trial
M/F, IC 32 2 g/d  3 months
(EPA:DHA
0.9:1.5)
Endothelial function,
inﬂammatory
function (CRP,
myeloperoxidase)
Improvement in
FMD, reduction in
soluble
thrombomodulin.
No change in
inﬂammation
Madden et al
(2009)82
Prospective study M, IC, and
Controls
205 6 g/d  12 weeks
(1.02 g EPA þ
0.69 g DHA)
CD44 and CD22v3
expression
Reduction in CD44,
increase in CD44v3
Flock et al
(2013)83
Randomized,
placebo-controlled,
double-blind,
parallel group study
M/F 115 0 mg, 300 mg,
600 mg, 900 mg,
1800 mg ﬁsh oil/
d  5 months
Omega-3 Index
(O3I)
O3I increased in a
dose-dependent
manner
Singhal et al
(2013)84
Randomized,
placebo-controlled,
double-blind
M/F 328 1600 mg DHA/d 
16 weeks
FMD, O3I,
triglycerides,
distensibility,
carotid intima-
media thickness
Signiﬁcant decrease in
FMD of
experimental group
Ruiz-Canela
et al (2014)85
Randomized,
blinded
M/F w/o PAD,
w/T2DM
7477 Med. diet þ extra
virgin olive oil;
Med. diet þ nuts
Incidence of PAD Lower incidence of
PAD in Med diet þ
extra virgin olive oil
group vs Med
diet þ nuts or
control group that
received only
dietary counseling.
ABI, Ankle-brachial index; CRP, C-reactive protein; DHA, docosahexanoic acid; EPA, eicosapentaenoic acid; F, females; FMD, ﬂow-mediated vasodilation;
IC, intermittent claudication; M, males; Med, Mediterranean; QOL, quality of life; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.
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dant properties, and ﬁber, which is associated with
lowering cholesterol levels, and may therefore be beneﬁcial
for counteracting the inﬂammatory and oxidative stress
states that prevail in PAD.49Supplementation with n-3 PUFAs at high doses may
cause mild gastrointestinal symptoms, namely a “ﬁshy
burp,” that can be mitigated by refrigerating ﬁsh oil cap-
sules before ingestion or consuming them with cool foods
or beverages.50 High intake of n-3 PUFAs has also been
Table III. Diet patterns recommended for primary and secondary prevention of cardiovascular disease
Diet pattern Nutritional recommendations Strength of evidencea Level of evidenceb
DASH diet Recommended to prevent hypertension and lower blood
pressure. The diet emphasizes sodium restriction,
reduction of fat intake, and alcohol avoidance
I A
Mediterranean diet A Mediterranean diet has been shown to improve quality
and life expectancy in patients with cardiovascular
disease, as well as those who have type 2 diabetes or are
overweight
Mediterranean diets have been found to be preferable to a
low-fat diet in increasing HDL-C blood levels,
reducing triglyceride levels, and improving insulin
sensitivity
IIa
IIa
A
A
Low-fat diet A low-fat diet has been shown to improve quality and life
expectancy in people with cardiovascular disease, as
well as in states of obesity and type 2 diabetes
IIa A
Low-carbohydrate diet A low-carbohydrate diet is effective at reducing
triglyceride levels and increasing HDL-C blood levels,
especially when compared with a low-fat diet
Low-carbohydrate diets, which include 30%-40% of
calories from carbohydrates and are low in saturated fat
and high in monounsaturated fat, were found to be safe
in healthy and overweight individuals at follow-up up
to 4 years
IIb
IIa
A
A
Ornish Spectrum Diet Emphasizes comprehensive lifestyle management,
including diet (low-fat, whole foods, plant-based),
exercise, stress management, and social support for
reversal of coronary heart disease and minimizing risk
for those with cardiovascular disease risk factors
No speciﬁc recommendation
from national guidelines
Weil Anti-inﬂammatory
diet
http://www.drweil.com/drw/u/ART02012/anti-
inﬂammatory-diet
Daily caloric intake should be between 2000 and 3000.
The distribution of calories should be as follows: 40%-
50% from carbohydrates, 30% from fat, and 20%-30%
from protein
Individuals are encouraged to consume carbohydrates,
fat, and protein with each meal
Speciﬁc recommendations on sources for carbohydrates,
protein, saturated fats, vitamins/minerals, and
supplements
No speciﬁc recommendation
from national guidelines
DASH, Dietary Approaches to Stop Hypertension; HDL-C, high-density lipoprotein cholesterol.
aStrength of statement/recommendation: Class IdEvidence and/or general agreement that a given statement and/or recommendation is beneﬁcial; Class
IIdConﬂicting evidence and/or a divergence of opinion about the usefulness/efﬁcacy of the statement and/or recommendation; Class IIadWeight of
evidence/opinion is in favor of usefulness/efﬁcacy; Class IIbdUsefulness/efﬁcacy is less well established by evidence/opinion; Class IIIdEvidence or general
agreement that the treatment is not useful/effective and, in some cases, may be harmful.
bLevels of evidence: AdData derived from multiple randomized clinical trials or meta-analyses; BdData derived from a single randomized clinical trial or large
nonrandomized studies; CdConsensus of opinion of the experts and/or small studies, retrospective studies, registries.
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This potential side effect has been evaluated in large
cohorts, and the aggregate results have not shown an
association with clinically signiﬁcant vascular effects or
risk.51,52
FOLATE, VITAMINS B6 AND B12
Deﬁciencies in folate or these critical B-series vitamins
may disrupt homocysteine homeostasis and yield an accu-
mulation of homocysteine. Such a state of hyperhomocys-
teinemia (when blood levels exceed 14 mmol/L) is
associated with an increased risk of PAD,16,53 as well as
an increased risk of myocardial infarction and stroke.
Because folic acid and vitamins B12 and B6 are involved
in homeostatic metabolism, it has been postulated thatsupplements could theoretically lead to a resolution of
normal physiologic levels and thereby reduce cardiovascu-
lar risk. Some studies that evaluated supplementation
among individuals with hyperhomocysteinemia have
shown biologic beneﬁt.54,55 However, other investigations
have failed to show a clinical beneﬁt from supplementation
with folic acid and B-series vitamins.26,56-59 Furthermore, a
recent meta-analysis of folic acid supplementation in pa-
tients with chronic kidney disease, a condition that is often
comorbid with advanced PAD, failed to show a beneﬁcial
effect in cardiovascular outcomes.59 Although folic acid
supplementation is generally not associated with detri-
mental effects, excessive intake may carry the risk of
enhancing development of premalignant lesions, particu-
larly in the colorectal tract.60
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Vitamin C is thought to exert protective effects on
endothelial cells and vascular smooth muscle cells during
the early steps in atherosclerosis by preventing endothelial
dysfunction and promoting type IV collagen synthesis.61
The vitamin diminishes recruitment and proliferation of
vascular smooth muscle cells in regions of vascular damage,
thereby lessening the oxidative stress that results from
macrophage activation.61 Following on these biochemical
observations, inverse associations have been made between
blood levels of vitamin C and inﬂammatory biomarkers,
most notably C-reactive protein, in large observational
population studies.62,63 Vitamin C levels have been
observed to be relatively low in PAD in several co-
horts.32,64 Despite this observation, there is a lack of pro-
spective trials examining the clinical effects of vitamin C
supplementation in this patient population or for cardiovas-
cular risk prevention. In certain populations, high doses of
vitamin C supplementation may even be related to detri-
mental cardiovascular mortality outcomes.65 The 2013
AHA/ACC Task Force Guidelines, therefore, do not
currently have recommendations for vitamin C.26
Vitamin D deﬁciency has also been associated with
PAD.16,26,66 Despite the association with a vitamin D-deﬁ-
cient state in PAD, no interventional studies have reported
clinically signiﬁcant effects of vitamin D supplementation
(with or without calcium) on cardiovascular events,
including myocardial infarction, stroke, and other cardiac
and cerebrovascular outcomes.26,67 In fact, the Women’s
Health Initiative trial found that combined vitamin D
and calcium supplementation may have a nearly signiﬁcant
detrimental effect.68 At this time, the AHA/ACC guide-
lines do not recommend screening blood vitamin D levels
for cardiovascular disease prevention, although they do
state that correction of decreased levels may improve car-
diovascular disease morbidity and mortality rates. Taking
these ﬁndings together, it is evident that vitamin D deﬁ-
ciency is a critical factor in PAD, although it is unclear
whether speciﬁc recommendations can be made for supple-
mentation. Ongoing studies such as the Vitamin D and
OmegA-3 Trial (VITAL) trial69 may yield critical informa-
tion on the role of vitamin D supplementation in vascular
health. Of note, toxicity from excessive vitamin D intake
may lead to increased calcium deposition in the vasculature
and thereby promote atherosclerosis as well as negative car-
diovascular sequelae, such as atrial ﬁbrillation.70
Vitamin E, also called a-tocopherol, is the only cell
membrane-bound lipid-soluble antioxidant, and deﬁ-
ciencies have been observed in PAD.31,32 Lower levels of
this antioxidant are thought to impair tolerance to ischemia
and worsen intermittent claudication.25 However, a 2000
Cochrane review71 that evaluated the effects of vitamin E
supplementation on intermittent claudication found that
the available data were inconsistent to favor recommending
vitamin E in PAD patients. Importantly, caution should be
used in recommending vitamin E supplementation to pa-
tients taking anticoagulants, such as warfarin, due to thesynergistic effects of vitamin E with these medications
and the increased risk for hemorrhagic events.72 The
2013 AHA/ACC Task Force Guidelines support not rec-
ommending supplemental vitamin E.26
COENZYME Q10
Formerly known as ubiquinone, coenzyme Q10 is
another physiologic antioxidant that has been shown to
positively affect cardiac performance in patients with
congestive heart failure and ischemic heart disease and to
exert a clinically signiﬁcant blood pressure-lowering ef-
fect.73 Although its exact mechanism of action is unclear,
it is thought that this potent antioxidant may promote
improved endothelial function. This hypothesis sparked
the design and execution of several supplementation tri-
als.74-76 A recent meta-analysis73 incorporated ﬁve ran-
domized controlled trials evaluating the effect of
coenzyme Q10 on arterial endothelial function and found
that endothelial function (as assessed by endothelium-
dependent ﬂow-mediated vasodilation) signiﬁcantly
improved. The authors concluded that supplementation is
warranted in patients with and without cardiovascular dis-
ease, although exact dosages are not established. In addi-
tion to a low number of aggregate studies, an important
limitation to this analysis is that the studies reviewed incor-
porated patient groups with varying cardiovascular disease
severity, including those with hyperlipidemia, type 2 dia-
betes mellitus, and CAD. Furthermore, no supplementa-
tion studies in PAD have been published. It is therefore
difﬁcult to draw conclusions about the role of coenzyme
Q10 in primary prevention of cardiovascular disease as
well as its role in secondary prevention in patients with
PAD. Side effects associated with coenzyme Q10 are un-
common, but those reported include nausea, vomiting,
diarrhea, and abdominal discomfort. In addition, coen-
zyme Q10 may have an antiplatelet effect and lead to an
increased bleeding risk.77 Supplementation studies in pa-
tients with PAD to evaluate the potential effects of the anti-
oxidant are warranted.
Our review of primary evidence did not show a clear
indication for routine testing of the nutrients presented
above and therefore, our group does not have a practice
of doing so in our vascular clinic. Despite this, our research
has raised a higher awareness of nutrition issues in patients
with PAD and the importance of a healthy diet is empha-
sized when discussing lifestyle modiﬁcations in our pa-
tients. Further well-conducted, large, multicentered, and
double-blinded investigations are warranted to see if
correction of deﬁciencies may improve clinical outcomes.
If these ﬁndings are observed in prospective studies, then
routine testing may be incorporated into clinical practice
in the future.
TYPES OF DIETS
From the available evidence and the recent AHA/ACC
Task Force Guidelines, Eilat-Adar et al34 proposed a
healthy lifestyle plan that can serve as a good foundation
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fresh or frozen food without added sugars, minimizing
intake of salt or high-calorie sauces, and using cooking
methods that preserve the original nutrients. The diet
should also include a diversity of vegetables, fruits, whole
grains, soluble ﬁbers, and legumes. Cooking with certain
vegetable oils, particularly olive and canola oils, but not co-
conut and palm oils, is preferred over animal fat. They also
propose eating at least two servings of fatty, oily ﬁsh (eg,
salmon, tuna, and mackerel) weekly, with each portion
size amounting to 55 to 85 g and supplying a minimum
of 500 to 1000 mg EPA and DHA.
Further steps that physicians can take to help curb asso-
ciated disability and mortality include instructing patients
about diet plans designed for and studied in cardiovascular
disease, such as the Dietary Approaches to Stop Hyperten-
sion (DASH) and Mediterranean diets, and connecting
them with resources that promote healthful nutrition.
The AHA and ACC highlight four studied dietary plans
that have been shown to improve cardiovascular disease
risk factors and outcomes in the setting of diagnosed car-
diovascular disease (Table III). Also included in Table III
are two additional noteworthy diets that have been
designed speciﬁcally for individuals with CAD or cardiovas-
cular disease risk factors: Dr Dean Ornish’s Spectrum Diet
and Dr Andrew Weil’s anti-inﬂammatory diet. Although
these diet plans maintain different aims, they all exemplify
the general task force recommendations and a few even
go further by promoting more personalized nutrition to
decrease disability and promote survival.34
Future studies that assess nutrition in PAD should
compare the AHA/ACC recommended diet plans, as
well as the Spectrum diet and the anti-inﬂammatory diet,
in this patient population to determine their utility, feasi-
bility, and effects on cardiovascular outcomes. Also,
because PAD is a complex and multifactorial disease, pro-
spective therapeutic efforts should incorporate a variety of
nutrients and evaluate whether long-term supplementation
affects claudication or survival, rather than focusing on sin-
gular nutrients.
CONCLUSIONS
PAD is a chronic inﬂammatory condition that is asso-
ciated with, among other risk factors, longstanding poor
nutrition habits. Owing to the systemic nature of athero-
sclerotic burden in PAD and the high risk of ischemic
events, patients with this condition should be considered
candidates for secondary prevention strategies that empha-
size lifestyle change, and particularly an improvement in
dietary habits. We advocate for an intensiﬁed use of diet
in PAD therapy and speciﬁcally recommend following a
diet that is rich in nutrients with anti-inﬂammatory and
antioxidant properties. Primary prevention for individuals
with associated risk factors is also critically important and
can be optimized by comprehensively evaluating an indi-
vidual’s long-term nutritional patterns, which provide
clues about risk prediction for PAD and cardiovascular dis-
ease in general. Enhancing public awareness about PAD isimperative, as is making societal efforts to promote better
nutrition to reduce the impact associated with this
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